Human AP0BEC3G (A3G ) mutates the HIV genome by deaminafing cDNA cytosines to uracils. This activity can inactivate HIV. However, as a counter-defense, HIV uses an auxiliary protein called Vif (virion infectivity factor) to degrade A3G. A direct protein-protein interaction is required for Vif to neutralize A3G. Although, high-resolution structures of the deaminase domain of A3G have been achieved recently (including two NMR structures from Matsuo laboratory), structures of the full-length A3G protein and its complexes with DNA or Vif have proven more elusive. APOBEC3F (A3F) is another potent HIV-1 restriction factor. Much less structural information is available for A3F as there is no high-resolution structure for this protein. Structural and biochemical studies of A3G and A3F have been hinderd by their insolubility. We have recently generated A3G and A3F variants that are folded, catalytically acitive and soluble enough to take NMR spectra. We propose to solve structures of full-length A3G, the catalytic domain of A3F and their complexes with Vif (or Vif fragments) using NMR. We will also interrogate the interactions between A3G/F and single-stranded DNA. Our objectives are to reveal structurally (1) intra- and inter-molecular domain-domain interaction of A3G and A3F, (2) their mechanisms for binding ssDNA and (S) similarities and differences between A3G and A3F in their Vif-binding domains. These studies are an integral part of a larger interdisciplinary program project that will generate unprecedented molecular, biochemical, biophysical and structural information on this critical host-pathogen interaction.

Public Health Relevance

Structural information of the HIV-1 restriction factors A3G and A3F will provide a strong foundation for further biochemical and cellular studies. In addition, an atomic-level understanding of the A3-Vif interaction can be used to rationally develop new therapeutic methods for HIV/AIDS.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-AARR-D)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Nowarski, Roni; Prabhu, Ponnandy; Kenig, Edan et al. (2014) APOBEC3G inhibits HIV-1 RNA elongation by inactivating the viral trans-activation response element. J Mol Biol 426:2840-53
Li, Jinhui; Chen, Yan; Li, Ming et al. (2014) APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells. J Mol Biol 426:1296-307
Macdonald, Patrick J; Johnson, Jolene; Chen, Yan et al. (2014) Brightness experiments. Methods Mol Biol 1076:699-718
Lyubchenko, Yuri L; Gall, Alexander A; Shlyakhtenko, Luda S (2014) Visualization of DNA and protein-DNA complexes with atomic force microscopy. Methods Mol Biol 1117:367-84
Lyubchenko, Yuri L (2014) Nanoscale Nucleosome Dynamics Assessed with Time-lapse AFM. Biophys Rev 6:181-190
Albin, John S; Brown, William L; Harris, Reuben S (2014) Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus. Virology 450-451:49-54
Matsui, Yusuke; Shindo, Keisuke; Nagata, Kayoko et al. (2014) Defining HIV-1 Vif residues that interact with CBF? by site-directed mutagenesis. Virology 449:82-7
Shlyakhtenko, Luda S; Lushnikov, Alexander J; Li, Ming et al. (2014) Interaction of APOBEC3A with DNA assessed by atomic force microscopy. PLoS One 9:e99354
Matsui, Masashi; Shindo, Keisuke; Izumi, Taisuke et al. (2014) Small molecules that inhibit Vif-induced degradation of APOBEC3G. Virol J 11:122
Land, Allison M; Shaban, Nadine M; Evans, Leah et al. (2014) APOBEC3F determinants of HIV-1 Vif sensitivity. J Virol 88:12923-7

Showing the most recent 10 out of 41 publications